PMID- 36217741
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20230303
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 13
IP  - 23
DP  - 2022 Dec
TI  - Long-term survival analysis of patients with stage IIIB-IV non-small cell lung 
      cancer complicated by type 2 diabetes mellitus: A retrospective propensity score 
      matching analysis.
PG  - 3268-3273
LID - 10.1111/1759-7714.14676 [doi]
AB  - BACKGROUND: This study aimed to determine the effect of type 2 diabetes mellitus 
      (T2DM) on overall survival (OS) of patients with stage IIIB-IV non-small cell 
      lung cancer (NSCLC). METHODS: We retrospectively analyzed patients with stage 
      IIIB-IV NSCLC from January 2015 to December 2018 in the Department of Oncology at 
      the First Affiliated Hospital of Anhui University of Traditional Chinese 
      Medicine. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards 
      regression models were used to describe the effect of T2DM on the OS of patients 
      with stage IIIB-IV NSCLC. RESULTS: This study collected data on 76 patients with 
      NSCLC and T2DM (group A) and 214 NSCLC patients without T2DM (group B). After 
      propensity score matching (PSM) analysis, 74 patients were included in each 
      group. The mean OS of all patients was 17 months (range, 11-31 months). The mean 
      OS of group A was 15 months (range, 8-25 months) and the mean OS of group B was 
      20 months (range, 14-39 months). The mean OS of group B was longer than group A, 
      and the difference was statistically significant. Univariate analysis of the 
      clinical data showed that T2DM and complications were significantly correlated 
      with the prognosis of patients with stage IIIB-IV NSCLC (p = 0.003 and 
      p = 0.034). Multivariate Cox model analysis showed that T2DM and complications 
      were independent prognostic factors for patients with stage IIIB-IV NSCLC 
      (p = 0.002 and p = 0.024, respectively). CONCLUSION: Stage IIIB-IV NSCLC patients 
      without T2DM have an increased OS compared to patients with stage IIIB-IV NSCLE 
      and T2DM.
CI  - (c) 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Li, Xuejiao
AU  - Li X
AD  - School of Nursing, Anhui University of Traditional Chinese Medicine, Hefei, 
      China.
FAU - Fang, Haiyan
AU  - Fang H
AD  - School of Nursing, Anhui University of Traditional Chinese Medicine, Hefei, 
      China.
FAU - Zhang, Dongwei
AU  - Zhang D
AD  - The First Department of Oncology, The First Affiliated Hospital of Anhui 
      University of Traditional Chinese Medicine, Hefei, China.
FAU - Xia, Liming
AU  - Xia L
AD  - The First Department of Oncology, The First Affiliated Hospital of Anhui 
      University of Traditional Chinese Medicine, Hefei, China.
FAU - Wang, Xiang
AU  - Wang X
AD  - School of Nursing, Anhui University of Traditional Chinese Medicine, Hefei, 
      China.
FAU - Yang, Jingping
AU  - Yang J
AD  - The First Department of Oncology, The First Affiliated Hospital of Anhui 
      University of Traditional Chinese Medicine, Hefei, China.
FAU - Zhang, Shaohu
AU  - Zhang S
AD  - The First Department of Oncology, The First Affiliated Hospital of Anhui 
      University of Traditional Chinese Medicine, Hefei, China.
FAU - Su, Ya
AU  - Su Y
AD  - The First Department of Oncology, The First Affiliated Hospital of Anhui 
      University of Traditional Chinese Medicine, Hefei, China.
FAU - Zhu, Yongfu
AU  - Zhu Y
AUID- ORCID: 0000-0002-8158-4102
AD  - The First Department of Oncology, The First Affiliated Hospital of Anhui 
      University of Traditional Chinese Medicine, Hefei, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221011
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
SB  - IM
CIN - Thorac Cancer. 2023 Jan;14(1):108-109. PMID: 36377375
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - Retrospective Studies
MH  - *Lung Neoplasms/pathology
MH  - Propensity Score
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
PMC - PMC9715843
OTO - NOTNLM
OT  - chemotherapy
OT  - diabetes mellitus
OT  - non-small cell lung cancer
OT  - survival
COIS- No authors report any conflict of interest.
EDAT- 2022/10/12 06:00
MHDA- 2022/12/06 06:00
PMCR- 2022/12/01
CRDT- 2022/10/11 03:13
PHST- 2022/09/15 00:00 [revised]
PHST- 2022/08/23 00:00 [received]
PHST- 2022/09/16 00:00 [accepted]
PHST- 2022/10/12 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/10/11 03:13 [entrez]
PHST- 2022/12/01 00:00 [pmc-release]
AID - TCA14676 [pii]
AID - 10.1111/1759-7714.14676 [doi]
PST - ppublish
SO  - Thorac Cancer. 2022 Dec;13(23):3268-3273. doi: 10.1111/1759-7714.14676. Epub 2022 
      Oct 11.